New blog post by Dr Graham Kelly just gone up on the website...

New blog post by Dr Graham Kelly just gone up on the website today…
https://www.noxopharm.com/site/blog/noxopharm-s-chemotherapy-program

Here’s the opening…..

”
Noxopharm's Chemotherapy Program

Posted on May 10th, 2021 . Updated on May 10th, 2021 by CEO Dr Graham Kelly

The significance of the announcement on Friday 7 May, 2021 lies in the Company putting on the public record its formal commitment to its 4-pillars oncology strategy. We have mentioned this strategy in recent times, but the Company’s recent commitment to the CEP-2 trial with the appointment of an overseeing contract research organisation, formalises the strategy.

Behind this strategy is an aim to see Veyonda become a standard way of making most common forms of cancer therapy work better.

Such an aim is about as big as you can have in oncology. It’s one that we are not aware of anyone trying before, but that is probably because no-one has a drug with the unique ability of idronoxil (the active ingredient in Veyonda) to restore cancer-fighting immune function to tumours. Restoring that immune function increasingly is being recognised as a pre-condition to all forms of effective anti-cancer therapy. In a field of very few competing technologies, the Company is confident, based on public disclosures, that Veyonda is the only technology that specifically addresses the mechanism responsible for expelling immune cells from tumours.**

4-pillars strategy

This strategy involves using Veyonda across the current 3 mainstays of cancer therapy, along with an emerging 4^th form of therapy - injectable radiopharmaceuticals:”……

Read the rest on the website. A truly excellent roadmap of where the company is aiming to be in the very near future.

Apples